A new meta-analysis led by researchers from the Fatty Acid Research Institute (FARI) provides the clearest picture to date of the relationship between omega-3 fatty acid supplementation and atrial fibrillation (AF), helping resolve years of confusion generated by earlier reports.
Published in Circulation: Arrhythmia and Electrophysiology, the study, led by Dr. Nada Abuknesha, PhD, an Associate Scientist at FARI, analysed data from 35 randomised controlled trials involving 114,592 participants—more than four times the number of studies included in previous meta-analyses. Researchers also incorporated unpublished trial data and previously unavailable safety information to provide the most comprehensive assessment of AF risk to date.
The analysis found that low-dose omega-3 supplementation (less than 1,500 mg/day EPA+DHA) was not associated with an increased risk of AF, even among individuals at elevated cardiovascular risk.
Visit: https://www.ahajournals.org/doi/10.1161/CIRCEP.125.014785